PPARβ/δ agonists mimicked obesity effects and inhibited trafficking of the cytotoxic machinery to the NK cell-tumor junction, disenabling NK cells to reduce tumor growth in obesity in vivo. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.